Five-year Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma: Intraocular Pressure Reduction, Surgical Success, and Safety
Journal of Medical Sciences · 2026-07 · 46 (4) · 196-204
DOI: 10.4103/jmedsci.jmedsci_57_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Sciences, online erschienen am 03.07.2026. Verfasst von Chia-Chen Hsu und 3 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Long-term real-world evidence regarding the efficacy and safety of micropulse transscleral cyclophotocoagulation (MPCPC) remains limited.
Aim
To evaluate the 5-year efficacy and safety of MPCPC in refractory glaucoma.
Methods
This single-center retrospective study evaluated 42 eyes of 30 patients who underwent MPCPC between January 1, 2019, and May 31, 2020. All procedures followed a standardized protocol using a 2.0 W power setting for 180 s. The primary outcome was surgical success, defined as an intraocular pressure (IOP) reduction of ≥20% from baseline. Secondary outcomes included changes in visual acuity, antiglaucoma medication burden, and the incidence of ocular adverse events.
Results
Mean IOP significantly decreased from 28.9 ± 11.6 mm Hg at baseline to 24.4 ± 10.4 mm Hg at 12 months and 21.5 ± 11.5 mm Hg at 60 months (all P < 0.05). Success rates were 54.3% at 1 year and 51.7% at 5 years. In the multivariable Firth regression model, each 1 mm Hg increase in baseline IOP was associated with a 16% increase in the probability of 1-year success (odds ratio: 1.16; 95% confidence interval: 1.05–1.29; P = 0.0048). While the topical medication burden remained unchanged, oral acetazolamide use significantly decreased at 1 month ( P = 0.039). Visual acuity declined in 58.1% of eyes at 5 years, largely attributable to disease progression in this refractory cohort. No severe complications, such as hypotony or phthisis bulbi, were observed.
Conclusion
MPCPC provides a sustained, long-term IOP-lowering effect with a favorable safety profile in a real-world refractory population. This study addresses a critical evidence gap by demonstrating treatment durability up to 5 years and identifying preoperative IOP as a key predictor of success in an ethnically Chinese cohort.
Zitieren
APA
Hsu, C., Liang, I., Lu, D., & Chen, Y. (2026). Five-year Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma: Intraocular Pressure Reduction, Surgical Success, and Safety. Journal of Medical Sciences, 46(4), 196-204. https://doi.org/10.4103/jmedsci.jmedsci_57_26
Vancouver
Hsu C, Liang I, Lu D, Chen Y. Five-year Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma: Intraocular Pressure Reduction, Surgical Success, and Safety. Journal of Medical Sciences. 2026;46(4):196-204. doi:10.4103/jmedsci.jmedsci_57_26
BibTeX
@article{Hsu2026,
author = {Hsu, Chia-Chen and Liang, I-Chia and Lu, Da-Wen and Chen, Yi-Hao},
title = {Five-year Outcomes of Micropulse Transscleral Cyclophotocoagulation in Refractory Glaucoma: Intraocular Pressure Reduction, Surgical Success, and Safety},
journal = {Journal of Medical Sciences},
year = {2026},
volume = {46},
number = {4},
pages = {196--204},
doi = {10.4103/jmedsci.jmedsci_57_26}
}
EUVIMED